{
 "id": "stroke",
 "name": "Stroke",
 "aliases": [],
 "acronyms": [],
 "bodySystem": "neurological",
 "parent": null,
 "children": [],
 "edition": "2026-11",
 "merkleRoot": "006ab9a329709cbe7f56a0e1a7c4a02f897655cdfecf9ca34d199690095adcb6",
 "builtFrom": "program.status and program.eligibility facts, grouped by the condition registry",
 "counts": {
  "open": 0,
  "limited": 0,
  "waitlist": 0,
  "closed": 1
 },
 "funds": [
  {
   "fund": "Stroke",
   "organization": "TotalAssist (Patient Advocate Foundation copay funds)",
   "status": "closed",
   "dateOnPage": null,
   "awardLevelUsd": 1500,
   "insuranceTypes": [
    "Medicaid",
    "Medicare",
    "TRICARE"
   ],
   "pageSays": "The page lists the fund as Closed.",
   "readOn": "2026-11-08",
   "source": "https://totalassist.org/funds/"
  }
 ],
 "drugsWhoseLabelNamesThisCondition": [
  {
   "ingredient": "APIXABAN",
   "pages": [
    {
     "brand": "Eliquis",
     "url": "https://omnirx.org/negotiated-drugs/eliquis"
    }
   ],
   "labelSentence": "... to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.",
   "labelContext": "risk-reduction",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22095a08ac-cf0e-497e-a682-ddef38d6b29c%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Eliquis 360 Support (via BMS/Pfizer)",
     "url": "https://omnirx.org/assistance/eliquis-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "BMS Access Support",
     "url": "https://omnirx.org/assistance/bms-access-support-eliquis",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Pfizer RxPathways",
     "url": "https://omnirx.org/assistance/pfizer-rxpathways",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": "limited",
     "statusRead": "2026-11-07"
    },
    {
     "name": "Heart Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/heart-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Bristol Myers Squibb Patient Assistance Foundation",
     "url": "https://www.bmspaf.org/#/medicines",
     "programPageIsExternal": true,
     "inCurrentList": true,
     "note": null,
     "listKind": "Medicines available through the Foundation",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 237.25,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "RIVAROXABAN",
   "pages": [
    {
     "brand": "Xarelto",
     "url": "https://omnirx.org/negotiated-drugs/xarelto"
    }
   ],
   "labelSentence": "... to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.",
   "labelContext": "risk-reduction",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2210db92f9-2300-4a80-836b-673e1ae91610%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Xarelto Savings (via Janssen/J&J)",
     "url": "https://omnirx.org/assistance/xarelto-patient-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "Heart Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/heart-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    },
    {
     "name": "J&J Patient Assistance Foundation (JJPAF)",
     "url": "https://omnirx.org/assistance/johnson-and-johnson-pap",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": "Medicines in the Quick Reference Guide picker on the program page",
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": {
    "usd30DaySupply": 202.33,
    "effective": "2027-01-01",
    "source": "https://www.cms.gov/initiatives/medicare-prescription-drug-affordability/overview/medicare-drug-price-negotiation-program/selected-drugs-negotiated-prices"
   }
  },
  {
   "ingredient": "Ticagrelor",
   "pages": [
    {
     "brand": "Brilinta",
     "url": "https://omnirx.org/medicines/brilinta"
    }
   ],
   "labelSentence": "Coronary Artery Disease but No Prior Stroke or Myocardial Infarction Ticagrelor tablets are indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events [see Clinical ...",
   "labelContext": "indication",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%221225fd45-9b56-1671-ee77-cd0c9f2174a5%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [
    {
     "name": "Heart Medication Assistance (Multiple Programs)",
     "url": "https://omnirx.org/assistance/heart-medication-assistance",
     "programPageIsExternal": false,
     "inCurrentList": true,
     "note": null,
     "listKind": null,
     "status": null,
     "statusRead": null
    }
   ],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Dabigatran Etexilate Mesylate",
   "pages": [
    {
     "brand": "Pradaxa",
     "url": "https://omnirx.org/medicines/pradaxa"
    }
   ],
   "labelSentence": "To reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation ( 1.",
   "labelContext": "risk-reduction",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%22ba74e3cd-b06f-4145-b284-5fd6b84ff3c9%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Icosapent Ethyl",
   "pages": [
    {
     "brand": "Vascepa",
     "url": "https://omnirx.org/medicines/vascepa"
    }
   ],
   "labelSentence": "... as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and ...",
   "labelContext": "risk-reduction",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%229c1a2828-1583-4414-ab22-a60480e8e508%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  },
  {
   "ingredient": "Simvastatin",
   "pages": [
    {
     "brand": "Simvastatin",
     "url": "https://omnirx.org/medicines/simvastatin"
    }
   ],
   "labelSentence": "... the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease ...",
   "labelContext": "risk-reduction",
   "labelSource": "https://api.fda.gov/drug/label.json?search=set_id:%2200896fff-081d-4553-be8c-1999a8a73dda%22&limit=1",
   "labelRead": "2026-11-10",
   "manufacturerPrograms": [],
   "medicareNegotiatedPrice": null
  }
 ],
 "fundsForRelatedCosts": [],
 "note": "Each status is what the fund page said on readOn. It is not an eligibility determination. We hold only the organizations we read; no fund here does not mean no fund exists.",
 "licence": "CC BY 4.0 for the OmniRx compilation"
}